94 results about "Sphingolipid" patented technology

The invention discloses a bacterial strain for degrading aspartame, a bacterial-algae symbiotic system and application of the bacterial strain and the bacterial-algae symbiotic system, the bacterial strain is corn sphingomonas zeae NCU J1, and the preservation number of the bacterial strain is CCTCC (China Center for Type Culture Collection) NO: M 20251462. And an algal-bacterial symbiotic system is constructed by adopting an oriented symbiotic combination of the corn sphingomonas NCU J1 and the chlorella sp. The corn sphingomonas NCU J1 can metabolize an artificial sweetening agent aspartame and degradation products thereof, metabolism complementation can be achieved through an algal-bacterial symbiotic interface, and bacteria preferentially promote aspartame to be subjected to photohydrolysis to generate degradation products such as diketopiperazine derivatives. The microalgae synchronously start isomerism enzymatic reaction to convert degradation products such as diketopiperazine derivatives into low-toxicity products, the risk of secondary pollution is reduced by 40% or above compared with that of a traditional physical and chemical method, 150 mg / L aspartame can be efficiently degraded within 2 days, generation of derivatives of aspartame can be greatly reduced, secondary pollution is reduced, and the method is suitable for industrial production. And the method has a good application prospect in the aspect of rapidly treating aspartame-containing wastewater.

The invention belongs to the technical field of RNA biological prevention and treatment, and particularly relates to application of dsRNA of a targeting sphingolipid C-4 hydroxylase coding gene. The invention provides application of targeted sphingolipid C-4 hydroxylase coding gene dsRNA in prevention and treatment of crop anthracnose and / or preparation of products for prevention and treatment of crop anthracnose, and the targeted sphingolipid C-4 hydroxylase coding gene dsRNA is obtained by transcription of partial sequence of a sphingolipid synthetase coding gene CsSUR2. The targeting sphingolipid C-4 hydroxylase coding gene dsRNA is loaded on the nano layered double hydroxide, so that the pathogenicity of colletotrichum gloeosporioides and mango colletotrichum gloeosporioides can be obviously reduced, and the application prospect of preventing crop anthracnose is achieved.

The invention provides a drug permeability clinical prediction model, a construction method thereof and a non-specific drug permeability evaluation method, and belongs to the technical field of biological medicine. The invention provides a construction method of a drug permeability clinical prediction model. According to the construction method, intestinal microorganism characteristics are introduced into model construction for the first time. The prediction performance of the constructed LGBM model containing the intestinal microorganism characteristics in the aspect of NAC permeability prediction is superior to that of other traditional business models. The invention also provides a serine-derived sphingolipid de novo synthesis pathway, which is different from the traditional sphingolipid de novo synthesis pathway, and is named as a cysteine sphingolipid metabolism pathway, NAC-derived cysteine may participate in the biosynthesis of microbial sphingolipid through covalent binding with palmitoyl-CoA, thereby damaging intestinal permeation of NAC.

The metabolic marker can be used for early diagnosis of heart failure, has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result, provides a basis for clinical decision, provides a certain basis for subsequent fundamental research and clinical research, and has potential application and research values. The metabolic marker comprises one or more of 1-(4-nitrophenyl) piperidine, sphingolipid d19: 3 / 23: 0, phosphatidyl ethanolamine 16: 1e / 22: 5, phosphatidyl ethanolamine 16: 1e / 22: 6, sphingolipid d14: 0 / 22: 1, 3-phosphoglyceric acid, phosphatidylcholine 15: 0 / 20: 4, phosphatidylcholine o-16: 1 / 18: 0, phosphatidylcholine 14: 0e / 20: 1, phosphatidylcholine 17: 0 / 18: 5, betaine, phosphatidylcholine 15: 0 / 18: 2 and phosphatidylcholine 18: 5e / 20: 4.

Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol, glucosylcholesterol; and modified by (b) ionizable lipids. The present disclosure also includes a method for preparing a modified lipid composition, the method comprises reconstituting (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol and / or glucosylcholesterol in the presence of (b) ionizable lipids to produce the modified lipid composition, and loading one or more heterologous functional agents into the modified lipid composition.

The invention relates to the technical field of gene engineering, and relates to a construction method of sgRNA with a pBD2 gene knocked out and a construction method of a pig intestine epithelial cell line with the pBD2 gene knocked out. According to a pBD2 gene sequence, sgRNA capable of targeting the gene is designed and synthesized, plasmids of a CRISPR / Cas9 system containing the sgRNA are constructed by using a molecular cloning and recombination technology, the plasmids are transfected into a pig small intestine epithelial cell line, gene editing is performed on a specific position of the pBD2 gene, and a stable monoclonal cell line with the pBD2 gene knocked out is obtained through puromycin drug screening. The homozygous pBD2 gene knockout cell strain obtained by the method is used as a cell model and can be used for exploring the effects of the pBD2 gene in the aspects of immunoregulation, sphingolipid metabolism, cell cycle and the like of small intestine cells.

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.

The present invention relates to the field of exosome preparation and application technology, and in particular to Sophora japonica exosomes and their use in the preparation of drugs for digestive tract mucosal barrier damage. The Sophora japonica exosomes have an average diameter of 100 to 500 nm, a surface membrane potential of ‑15 to ‑85 mV, and contain 51.7% fatty acyl groups, 17.7% glycerophospholipids, 7.9% glycerolipids, 7.4% sphingolipids, 6.9% sterol lipids, 5.9% pro-alcohol lipids and 2.5% polyketide compounds in the Sophora japonica exosomes by mass percentage.

The invention provides a nano-emulsion composition, a nano skin care product, a preparation method and application, the nano-emulsion composition comprises a nano-emulsion and nucleic acid loaded on the surface of the nano-emulsion, and the nano-emulsion comprises a functional component, an emulsifier, an emollient, an antioxidant, a humectant and water; the functional component comprises a barrier repair lipid, the barrier repair lipid comprises sphingolipid, the sphingolipid comprises phytosphingosine, and the barrier repair lipid further comprises one or more of ceramide, free fatty acid and cholesterol; the mass ratio of the nucleic acid in the nanoemulsion composition is 0.1%-0.6%. The nanoemulsion composition has excellent permeability, so that the skin permeability of the nucleic acid is improved, and the bioavailability of the nucleic acid is improved; meanwhile, the nucleic acid can be specifically bound with adenosine A2A receptors distributed on keratinocytes, so that the binding speed of the nano-emulsion and the cells can be increased, the absorption and action effects of the nano-emulsion are specifically promoted, and the resistance of the skin to light aging is improved.

The present application provides a method for culturing CAR-T cells and its application in tumor treatment, belonging to the field of biomedical technology. Specifically, the method includes culturing CAR-T cells with sphingolipid metabolites. Culturing CAR-T cells with sphingolipid metabolites in vitro can significantly increase the killing efficiency of CAR-T cells, slow down the tumor growth rate, extend the survival period of patients / animals, and will not impose an additional metabolic burden on the body, with lower toxic and side effects. In addition, this method does not perform any modification on the cells themselves, thus reducing the unknown potential risks for patients / animals due to the reinfusion of various modified adjuvants, and therefore has higher safety.

The present invention provides the use of at least one sphingolipid for a hair treatment for inducing hair growth and / or inhibiting hair loss, including eyelashes and eyebrows. Said sphingolipid is preferably a ceramide having a fatty acid with a long hydrocarbon chain of C18-C24, mostly C20-C22, and a phytosphingosine base. Furthermore, and advantageously, the treatment is global, capable to also improve the properties of the scalp and hair themselves.

This invention provides a sea cucumber ganglioside extract nanoliposome with neuroprotective activity and its preparation method. The preparation steps are as follows: thawed frozen ready-to-eat sea cucumber, chopped, freeze-dried, pulverized, and sieved to obtain freeze-dried powder. The powder is then extracted using supercritical CO2 extraction and rotary evaporation to remove the solvent. This powder is then dissolved in anhydrous ethanol with soybean lecithin and β-sitosterol as the oil phase, mixed with PBS buffer, stirred, and hydrated to obtain a proemulsion. After centrifugation, the precipitate is resuspended and sonicated to obtain the product. This invention uses supercritical CO2 extraction, and the extract contains 59.70 μg / g of gangliosides, with glycosphingolipids accounting for 96.372% of sphingolipids, resulting in enrichment of the target components. Simultaneously, these nanoliposomes significantly delay Aβ1-42-induced paralysis. The 30 μg / mL group showed a 2.75-fold increase in motor ability and a 30% increase in reproductive function compared to the control group, and a 47% reduction in ROS levels. The neuroprotective effect is superior to that of the unencapsulated extract, providing a new approach for adjuvant intervention in neurodegenerative diseases such as Alzheimer's disease, and has broad application prospects in the functional food field.

The invention discloses lipidosome, a medicine lipidosome compound and a preparation method and application of the medicine lipidosome compound. The liposome comprises the following components in parts by mass: 10-65 parts of saturated phospholipid; 25 to 75 parts of unsaturated phospholipid; 0.5 to 15 parts of a trigger lipid; the trigger lipid is sphingolipid and / or cholesterol; the mass ratio of the saturated phospholipid to the unsaturated phospholipid is (0.20-2.50): 1. When the lipidosome is used for drug encapsulation, high encapsulation efficiency can be guaranteed, high activity of drugs can be maintained, the lipidosome can be stably stored, and a universal carrier is provided for drugs with different physicochemical properties (especially highly hydrophilic drugs, such as protein drugs and nucleic acid drugs).

Provided herein are methods for determining the disease progression of a subject having a prostate cancer.

The application discloses a MALDI-FT-ICR mass spectrum probe for single-chain sphingolipid detection and a preparation method and a use method thereof, and relates to the technical field of analytical testing. The MALDI-FT-ICR mass spectrum probe for single-chain sphingolipid detection has the general structure of: the preparation method comprises the following steps: 4-pyridine propionic acid or pyridine 4-propenoic acid is reacted with salicylaldehyde or a salicylaldehyde derivative in a protective atmosphere. The use method comprises the following steps: different concentrations of sphingosine methanol solutions are prepared, the stock solution of the probe is added into each concentration of the sphingosine methanol solution, and a mixed solution is obtained; the mixed solution is mixed with a matrix methanol solution, is spotted on a target plate, is dried at room temperature, and then is subjected to MALDI analysis; and a standard curve is drawn with different concentrations of the sphingosine in the step S1 as the horizontal coordinate and the MALDI ion signal intensity of the product obtained in the step S1 as the vertical coordinate. The mass spectrum probe provided by the application has high sensitivity, low cost and high throughput.

The invention provides a glucosinolate mass spectrum database and a construction method and application thereof, and the database records more than 120 types of glucosinolate molecular information which is far better than that of the existing database. According to the pretreatment and detection method for the targeted thioglycoside group of the biological sample, solid-phase extraction and a micro-nano mass spectrum chip are combined, thioglycoside group mass spectrum signals are obtained in batches under the condition of no matrix spraying, the coverage rate is wide, the flux is high, the detection speed is high, thioglycoside group information of multiple samples can be obtained at a time in an automatic detection mode, and the detection method is suitable for large-scale popularization and application. The obtained thioglycoside spectrogram is high in stability, and in-batch and inter-batch CVlt is achieved under the condition that no internal standard is added; by combining with an established thioglycoside mass spectrum database, a novel method strategy is provided for marker mining and clinical application of diseases related to sphingolipid.

Disclosed in the present invention are a sphingolipid metabolic marker, an analysis method therefor and a use thereof. The sphingolipid metabolic marker can be effectively used for early diagnosis, course monitoring and prognosis assessment of asthma, and has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result. The sphingolipid metabolic marker at least comprises one of the following substances: galactosylceramide d18:1 / 16:0 and galactosylceramide d18:1 / 14:0.

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-COV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.

The present invention relates to a novel and efficient process for the production of sphingolipids via N-acylation of hemolytic sphingolipids, such as o-red-phytosphingosine, salts thereof or analogs thereof. The process comprises the use of an ester as an acylating agent in the presence of a base and in a hydrocarbon solvent, and is particularly useful for the production of ceramides.

A composition has at least one self tanning agent and certain sphingolipids and / or certain sphingoid bases. Cosmetic formulations having the composition with at least one self tanning agent, certain sphingolipids and / or certain sphingoid bases enhance a self tanning effect of a self tanning agent or find application in cosmetic products for tanning of a human skin.

A composition for treating dry skin includes therapeutically active concentrations of one or more skin protecting lipids in an oleaginous base. The skin protecting lipids can include a sphingolipid and at least one oil. The composition is intended for application on the skin surrounding the eyes. The composition is configured to form a protective, occlusive layer that can moisturize the skin and reduce inflammation and itching without stinging, burning, or stripping the skin. According to an exemplary embodiment, the composition is formulated as a high viscosity ointment or gel.

The invention relates to the field of cosmetics, in particular to a bionic inclusion with a superconductive permeation enhancing effect, a preparation method of the bionic inclusion and the cosmetics. The bionic inclusion comprises a water phase, an oil phase and an active substance; the active substance comprises an oil-soluble active substance and / or a water-soluble active substance; the oil phase comprises an oil-soluble active matter and / or the water-soluble active matter comprises a water-soluble active matter; the oil phase comprises a skin lipid composition; the skin lipid composition is prepared from the following components in parts by weight: 0.01 to 10 parts of sphingolipids, 0.01 to 10 parts of phosphatidylcholine, 0.01 to 10 parts of cholesterol and 0.01 to 10 parts of fatty acid. The bionic inclusion is highly similar to a skin cuticle structure, and has a multi-level structure which can effectively wrap an active matter. Meanwhile, the formed multi-level structure can be better fused with skin lipid, the permeation effect of active substances is improved, and the active substances are promoted to permeate into the skin in a super-effective mode.

A method and markers for identifying cold sensitivity of different peach varieties, which relates to the field of fruit preservation technologies. According to lipid metabolomics identification and big data analysis, compositions of sphingolipids in different peach varieties are extracted, common components of sphingolipids of different varieties are compared, so as to provide a method for identifying a CI process of different peach varieties based on sphingolipid metabolism.

The present invention provides the use of the combined use of bilirubin, chondroitin sulfate and licofelone in the preparation of a medicament for treating osteoarthritis. The present invention also provides a sequential targeted drug delivery system for treating arthritis, which is prepared from bilirubin, chondroitin sulfate and licofelone as raw materials, and the molar ratio of the bilirubin, chondroitin sulfate and licofelone is: 1-10 parts of bilirubin, 1-20 parts of chondroitin sulfate, and 0.1-5 parts of licofelone. The present invention also provides a preparation method and use of the sequential targeted drug delivery system. The present invention discovers for the first time the synthesis of chondroitin sulfate modified with bilirubin, and encapsulates licofelone through the self-assembled micelles of the polymer, thereby realizing sequential drug delivery, efficiently regulating the abnormal sphingolipid metabolism and AA metabolism of M1 macrophages, and thus converting them into M2 macrophages. In addition, the delivery system of the present invention can prolong the residence and action time of licofelone in the joint.

In various embodiments, provided herein are host cells, methods, and pharmaceutical compositions, including complex sphingolipids, such as monosialic acid ganglioside 1 (GM1), monosialic acid ganglioside 2 (GM2), and monosialic acid ganglioside 3 (GM3). In some embodiments, the present disclosure provides biological production of glycosphingolipids. In still further embodiments, the present disclosure provides for the biological production of gangliosides.

The present invention relates to a lipid system comprising: a) at least one oil, b) at least one ionizable lipid, c) at least one sphingolipid, and d) at least one lipid-polymer, with the proviso is that the lipid system does not comprise cholesterol. The present invention also uses of the lipid system in therapy.

The present invention relates to a novel glycosynthase, especially an endoglycoceramide synthase, and to a method for the glycosylation of sphingolipids.

In various embodiments, host cells, methods, and pharmaceutical compositions comprising complex sphingolipids such as monosialoganglioside 1 (GM1), monosialoganglioside 2 (GM2), and monosialoganglioside 3 (GM3) are provided herein. In some embodiments, the disclosure provides the bioproduction of sphingoglycolipids. In yet another embodiment, the disclosure provides the bioproduction of gangliosides.

The application of ceramide in the control of rice blast fungus falls within the field of biological control. This invention relates to the application of ceramide in the control of rice blast fungus: a combination of ceramide and lipopeptides is used for the control of rice blast fungus. Exogenous addition of ceramide significantly enhances the stress effect of lipopeptides on rice blast fungus. It also enhances the abnormal accumulation of glycogen and lipid droplets in conidia, promotes the bursting of ROS, and increases intracellular ceramide and calcium... 2+ The invention increases the content of malondialdehyde (MDA) in mycelium, enhances membrane lipid peroxidation, and decreases ergosterol content. Furthermore, it inhibits the expression of ergosterol synthesis genes, UPR target genes, and sphingolipid metabolism-related genes. This invention develops a highly efficient natural agent against rice blast by combining exogenous Cer with lipopeptides. This agent effectively reduces the pathogenicity of rice blast fungus and significantly inhibits its infection of rice, laying the foundation for the development of novel biological control agents.

The present application relates to the field of microbial technology, and particularly relates to a strain of Matuura sphingolipid bacteria HPD1 for degrading high-efficiency fluazifop-butyl acid and application thereof, the Matuura sphingolipid bacteria HPD1 is classified and named as Novosphingobium mathurense , which was preserved in the China General Microbiological Culture Collection Center on May 9, 2026, with a preservation number of CGMCC No. 38610 and a preservation address of No. 1, Beichen West Road, Chaoyang District, Beijing. The Matuura sphingolipid bacteria HPD1 and the microbial inoculant thereof can effectively degrade high-efficiency fluazifop-butyl acid in a wide pH and temperature range, can be used as excellent functional bacteria for degrading pesticide residues, and can be used in the biological remediation of residual high-efficiency fluazifop-butyl acid in water bodies, contaminated soil, coastal wetland sediments and Spartina alterniflora treatment areas, and can provide functional bacteria resources that can be repeatedly obtained and environmentally friendly microbial remediation technology.